Inovio Pharmaceuticals Inc (NASDAQ: INO) on Tuesday, plunged -3.52% from the previous trading day, before settling in for the closing price of $2.27. Within the past 52 weeks, INO’s price has moved between $1.74 and $14.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 97.63% over the past five years. The company achieved an average annual earnings per share of 30.90%. With a float of $35.80 million, this company’s outstanding shares have now reached $36.10 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is -767.0%, operating margin of -58709.67%, and the pretax margin is -12414736.82%.
Inovio Pharmaceuticals Inc (INO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Inovio Pharmaceuticals Inc is 0.82%, while institutional ownership is 26.78%.
Inovio Pharmaceuticals Inc (INO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 30.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.92% during the next five years compared to 13.49% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Inovio Pharmaceuticals Inc (INO) is currently performing well based on its current performance indicators. A quick ratio of 3.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 395.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.92 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (NASDAQ: INO) saw its 5-day average volume 0.92 million, a negative change from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 76.80%. Additionally, its Average True Range was 0.19.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 8.56%, which indicates a significant decrease from 65.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.59% in the past 14 days, which was higher than the 99.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.91, while its 200-day Moving Average is $7.06. Nevertheless, the first resistance level for the watch stands at $2.25 in the near term. At $2.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.38. If the price goes on to break the first support level at $2.13, it is likely to go to the next support level at $2.06. The third support level lies at $2.00 if the price breaches the second support level.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
Market capitalization of the company is 79.06 million based on 26,100K outstanding shares. Right now, sales total 830 K and income totals -135,120 K. The company made 100 K in profit during its latest quarter, and -32,240 K in sales during its previous quarter.
